AIKENING Gx390 Recoil Starter Pull Start Assembly with Recoil Starter Rope Pull for Honda Recoil Starter(Pack of 2) Recoil Starter Rope X3 Bolts X9

Product Information

Chong H, Yao X, Zhang C, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE. 2012;7(3). Accessed April 4, 2023 Uğurlu, M.; Karaoğlu, M.H. Removal of AOX, total nitrogen and chlorinated lignin from bleached Kraft mill effluents by UV oxidation in the presence of hydrogen peroxide utilizing TiO 2 as photocatalyst. Environ. Sci. Pollut. Res. 2009, 16, 265–273. [ Google Scholar] [ CrossRef] [ PubMed] On September 29, 2021, an article entitled Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China was published in the international medical journal -- Infectious Diseases and Therapy. This clinical study is the world’s largest and China’s first prospective cohort study on the HIV PEP population to evaluate the safety, tolerability and adherence of the combination regimens of ABT with other oral drugs for HIV PEP. This study is supported by reliable sources of clinical studies and data collection, providing a clinical reference for evidence-based use in the treatment of HIV PEP. In the embryo-fetaldevelopment toxicity studyin rabbit, the pregnantrabbitswere given Albuvirtide by intravenous injection at dose levels of15, 30and 60 mg/kg once every 3days from the 6thto 18thday of pregnancy.In the highest dose of 60 mg/kg group, only 1 rabbit (1/13) delivered prematurely,and the percentage ofdysostosisof hyoid boneshowed an upward trend compared with that of the control group. There were no significant abnormal changes in appearance, bone and internal organs in the other pregnant rabbits and fetal rabbits. The NOAEL of Albuvirtidefor the parental rabbits, and embryos-fetus development were all 30 mg/kg, i.e. 3.9foldsof human equivalent dosecalculatedin terms of exposure. Toxicokinetic study showed nosignificant accumulation of Albuvirtide in pregnant rabbits.

Currently there is limited data on antiviral therapy for hospitalized AIDS patients with complicated opportunistic infections. The two-drug regimen containing ABT can rapidly inhibit viral replication, improve cellular immune function of patients, and is safe and effective for treatment naive and experienced patients withlow CD4+ T cell count.The phase 3 trial randomized 418 patients; more than 25% of patients were female and more than 70% patients had resistance to at least two drug classes. Further, approximately 25% of patients had CD4 cell count of less than 100, indicating advanced HIV disease with highly compromised immunity, who were at high risk of opportunistic diseases and death. In other words, this was a patient population that was relatively difficult to treat. One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of albuvirtide listed above. ChiCTR-TRC-13003140 Two Phase I, one Phase II clinical trials of AIKENING TMhave been completed, and one Phase IIIis ongoing and an interim analysis is reported. A total of 294 infected subjects were enrolled in the trials.170 patients with HIV-1 infection have been exposed to AIKENING TM.The safety assessment of AIKENING TMwas primarily based on theongoing randomized, controlled phase III clinical trial (TALENT study) in HIV-1 infected patients previously treated with antiretrovirals, in which the treatment group received the AIKENING TM(onceaweek, intravenousinfusion) and Lopinavir/ Ritonavir (LPV/r) combination therapy, and the control group received the standard 3-drug regimen of LPV/r + Tenofovir (TDF) or Zidovudine (AZT) + Lamivudine (3TC). Theinterim analysis summarized the safety data ofthe treatment group(n = 93) and the control group(n = 99) patients who completed24 to 48-weektreatment. The two-drug regimen with different targets is the future trend of ART research. It is worthy and we are looking forward to continuing to develop new HIV combinations of high efficacy and good tolerability for our patients."

Study Purpose: The purpose of this open-label trial was to evaluate 1) the drug-drug interaction between albuvirtide and lopinavir/ritonavir and 2) the short-term safety and efficacy of albuvirtide plus lopinavir/ritonavir. Purpose: The purpose of this study is to evaluate the safety of combination therapy with albuvirtide plus 3BNC117 and determine whether this combination can control viral load levels after an analytical treatment interruption of ART. 9Anastasia Batrak, Vice President of strategic marketing and product portfolio development at R-Pharm, said, “The drug-resistant strains of HIV are a serious threat to public safety. In Russia, 6-7% of newly treated patients have HIV resistance. Therefore, with the help of Frontier Biotech, we decided to introduce Aikening® to the Russian market, which can effectively treat patients suffering from HIV and developing drug resistance. The drug has been widely used in China. The combination therapy of Aikening® and 3BNC117 (broad-spectrum neutralizing antibody) is currently undergoing clinical trials in the United States and China. "